Rassie Kate, Alesi Simon, Neven Adriana C H, Mason Taitum, Jona Eveline, Ellery Stacey J, Enticott Joanne, Mousa Aya, Joham Anju E, Simmons David, Teede Helena
Monash Centre for Health Research and Implementation (MCHRI), Faculty of Medicine, Nursing and Health Sciences, Monash University, Melbourne, Victoria, Australia.
Department of Diabetes, Monash Health, Melbourne, Victoria, Australia.
Acta Obstet Gynecol Scand. 2025 Sep;104(9):1694-1704. doi: 10.1111/aogs.70000. Epub 2025 Jun 25.
Human placental lactogen (hPL) is a placental hormone which, according to preclinical research, appears to have key metabolic roles in pregnancy. We aimed to examine pregnancy hPL levels in relation to maternal metabolic parameters and fetal outcomes within an ethnically diverse cohort at high metabolic risk. Design was an observational cohort study, nested within a randomized controlled trial.
Pregnant women (n = 130), recruited for high metabolic risk, underwent measurement of hPL, plus clinical and metabolic parameters, in early pregnancy (15.8 ± 2.5 weeks of gestation). Univariable and multivariable simple linear regression models were used to examine relationships between early pregnancy hPL and key maternal anthropometric and biochemical variables. Fifty-four women progressed to serial measurement of hPL and metabolic parameters across pregnancy. Univariable and multivariable mixed effects regression models were used to explore relationships between hPL and maternal variables across pregnancy, with repeated measures adjusted for using random effects.
In early pregnancy, lower hPL levels were independently associated with higher maternal fasting glucose (β = -1.03, p < 0.01). Early pregnancy hPL was not significantly related to maternal obesity, gestational diabetes mellitus (GDM), or polycystic ovary syndrome status. In women with GDM, sampled serially across pregnancy, maternal hPL and leptin levels were inversely associated (adjusted β = -0.098, p ≤ 0.001). There was a significant relationship between higher late pregnancy hPL and increased infant birthweight in the serially sampled GDM cohort, both before (β = 50.81, p = 0.01) and after (β = 41.78, p = 0.02) adjustment for gestational age at birth.
Maternal hPL may play a role in maternal metabolic adaptation to pregnancy, particularly in relation to glucose and leptin dynamics. hPL in late pregnancy is positively associated with infant birthweight in women with GDM. Future studies of hPL in well-defined contemporary populations are warranted, both to understand mechanistic interactions in pregnancy and potentially as a biomarker for infant birthweight.
人胎盘催乳素(hPL)是一种胎盘激素,根据临床前研究,它在妊娠过程中似乎具有关键的代谢作用。我们旨在研究在一个具有高代谢风险的种族多样化队列中,妊娠期间hPL水平与母体代谢参数和胎儿结局之间的关系。研究设计为一项观察性队列研究,嵌套在一项随机对照试验中。
招募了130名具有高代谢风险的孕妇,在妊娠早期(妊娠15.8±2.5周)测量hPL以及临床和代谢参数。使用单变量和多变量简单线性回归模型来研究妊娠早期hPL与关键母体人体测量学和生化变量之间的关系。54名女性在整个孕期进行了hPL和代谢参数的系列测量。使用单变量和多变量混合效应回归模型来探索整个孕期hPL与母体变量之间的关系,并使用随机效应调整重复测量。
在妊娠早期,较低的hPL水平与较高的母体空腹血糖独立相关(β=-1.03,p<0.01)。妊娠早期hPL与母体肥胖、妊娠期糖尿病(GDM)或多囊卵巢综合征状态无显著相关性。在整个孕期进行系列采样的GDM女性中,母体hPL和瘦素水平呈负相关(调整后的β=-0.098,p≤0.001)。在系列采样的GDM队列中,妊娠晚期较高的hPL与婴儿出生体重增加之间存在显著关系,在调整出生时的胎龄之前(β=50.81,p=0.01)和之后(β=41.7